Shares in Evgen Pharma plc more more than doubled in value after the biotech signed a deal worth up to $160.5 million with Stalicla SA, to develop sulforaphane-based drug SFX-01 for certain patients with autism spectrum disorder.
CSL Ltd. subsidiary Seqirus inked a $30.1 million deal with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop and evaluate two influenza A subtype H2Nx (avian flu) vaccines in a phase I trial.
There’s further drama at troubled Belgian biotech Bone Therapeutics SA, but its CEO told BioWorld that its partner’s decision to return rights to cell therapy platform Allob is a blessing in disguise that could allow it to negotiate a more favorable deal, after a lifeline merger was delayed.
Bristol Myers Squibb Co.'s ongoing investment in protein degradation, a field electrified by both high scientific interest and potentially big-dollar deals, expanded Oct. 4 to include a new research collaboration with Synthex Inc. Valued at up to $550 million for Synthex, plus possible royalties, the license agreement will see the pair use genetic engineering technologies to develop small-molecule degraders across multiple targets. BMS also made an up-front payment and investment in Synthex of undisclosed value.
In what may just be the takeover effort’s first volley, Sumitovant Biopharma Ltd., a subsidiary of Sumitomo Pharma Co. Ltd., made a hefty offer for Myovant Sciences Ltd. – which said no. Shares of Myovant (NASDAQ:MYOV) closed at $24.44, up $6.48, or 36.1% on word of the unsolicited buyout proposal.
Simcere Pharmaceutical Group has out-licensed its autoimmune drug candidate SIM-0278 for all indications to Almirall SA in a deal worth up to $507 million. Simcere granted exclusive global rights to the candidate to Almirall for development and commercialization excluding mainland China, Hong Kong, Macau, and Taiwan. In return, Almirall will pay Simcere $15 million up front.
Zai Lab Ltd. has agreed to pay $30 million up front to in-license from Seagen Inc. exclusive rights to the antibody-drug conjugate (ADC) Tivdak (tisotumab vedotin) in mainland China, Hong Kong, Macau and Taiwan.
Incyte Corp. has agreed to acquire Villaris Therapeutics Inc., the developer of a monoclonal antibody for vitiligo that aims to treat a larger proportion of the skin than an available topical cream, for $70 million up front, plus up to $310 million in potential development and regulatory milestone payments. The deal includes up to $1.05 billion in commercial milestones on net sales of auremolimab, a preclinical MAb that works against IL-15Rβ and is expected to reach the clinic in 2023.
In what may just be the takeover effort’s first volley, Sumitovant Biopharma Ltd., a subsidiary of Sumitomo Pharma Co. Ltd., made a hefty offer for Myovant Sciences Ltd. – which said no. Shares of Myovant (NASDAQ:MYOV) closed at $24.44, up $6.48, or 36.1% on word of the unsolicited buyout proposal.
Simcere Pharmaceutical Group has out-licensed its autoimmune drug candidate SIM-0278 for all indications to Almirall SA in a deal worth up to $507 million. Simcere granted exclusive global rights to the candidate to Almirall for development and commercialization excluding mainland China, Hong Kong, Macau, and Taiwan. In return, Almirall will pay Simcere $15 million up front.
RSS
